vs
Apellis Pharmaceuticals, Inc.（APLS）与CORCEPT THERAPEUTICS INC（CORT）财务数据对比。点击上方公司名可切换其他公司
CORCEPT THERAPEUTICS INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$202.1M vs $199.9M），CORCEPT THERAPEUTICS INC净利率更高（12.0% vs -29.5%，领先41.5%），CORCEPT THERAPEUTICS INC同比增速更快（11.1% vs -5.9%），CORCEPT THERAPEUTICS INC自由现金流更多（$38.4M vs $-14.3M），过去两年CORCEPT THERAPEUTICS INC的营收复合增速更高（17.3% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Corcept Therapeutics是一家制药企业，专注于严重代谢疾病、精神疾病及肿瘤疾病治疗药物的发现、开发与商业化。公司围绕皮质醇过量带来的不良影响展开研究，致力于开发可缓解相关症状的新型化合物，管理团队由首席执行官兼总裁、董事Joseph K. Belanoff医学博士领导。
APLS vs CORT — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $202.1M |
| 净利润 | $-59.0M | $24.3M |
| 毛利率 | — | 98.7% |
| 营业利润率 | -25.6% | 2.2% |
| 净利率 | -29.5% | 12.0% |
| 营收同比 | -5.9% | 11.1% |
| 净利润同比 | -62.2% | -21.0% |
| 每股收益（稀释后） | $-0.40 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $202.1M | ||
| Q3 25 | $458.6M | $207.6M | ||
| Q2 25 | $178.5M | $194.4M | ||
| Q1 25 | $166.8M | $157.2M | ||
| Q4 24 | $212.5M | $181.9M | ||
| Q3 24 | $196.8M | $182.5M | ||
| Q2 24 | $199.7M | $163.8M | ||
| Q1 24 | $172.3M | $146.8M |
| Q4 25 | $-59.0M | $24.3M | ||
| Q3 25 | $215.7M | $19.7M | ||
| Q2 25 | $-42.2M | $35.1M | ||
| Q1 25 | $-92.2M | $20.5M | ||
| Q4 24 | $-36.4M | $30.7M | ||
| Q3 24 | $-57.4M | $47.2M | ||
| Q2 24 | $-37.7M | $35.5M | ||
| Q1 24 | $-66.4M | $27.8M |
| Q4 25 | — | 98.7% | ||
| Q3 25 | — | 97.8% | ||
| Q2 25 | — | 98.2% | ||
| Q1 25 | — | 98.5% | ||
| Q4 24 | — | 98.4% | ||
| Q3 24 | — | 98.4% | ||
| Q2 24 | — | 98.5% | ||
| Q1 24 | — | 98.3% |
| Q4 25 | -25.6% | 2.2% | ||
| Q3 25 | 48.7% | 4.9% | ||
| Q2 25 | -18.6% | 13.7% | ||
| Q1 25 | -50.0% | 2.2% | ||
| Q4 24 | -12.3% | 13.9% | ||
| Q3 24 | -24.0% | 25.5% | ||
| Q2 24 | -14.7% | 21.7% | ||
| Q1 24 | -36.0% | 20.1% |
| Q4 25 | -29.5% | 12.0% | ||
| Q3 25 | 47.0% | 9.5% | ||
| Q2 25 | -23.6% | 18.1% | ||
| Q1 25 | -55.3% | 13.1% | ||
| Q4 24 | -17.1% | 16.9% | ||
| Q3 24 | -29.2% | 25.9% | ||
| Q2 24 | -18.9% | 21.7% | ||
| Q1 24 | -38.5% | 18.9% |
| Q4 25 | $-0.40 | $0.20 | ||
| Q3 25 | $1.67 | $0.16 | ||
| Q2 25 | $-0.33 | $0.29 | ||
| Q1 25 | $-0.74 | $0.17 | ||
| Q4 24 | $-0.30 | $0.25 | ||
| Q3 24 | $-0.46 | $0.41 | ||
| Q2 24 | $-0.30 | $0.32 | ||
| Q1 24 | $-0.54 | $0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $372.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $647.8M |
| 总资产 | $1.1B | $836.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $372.2M | ||
| Q3 25 | $479.2M | $421.7M | ||
| Q2 25 | $370.0M | $342.2M | ||
| Q1 25 | $358.4M | $322.8M | ||
| Q4 24 | $411.3M | $383.3M | ||
| Q3 24 | $396.9M | $380.3M | ||
| Q2 24 | $360.1M | $473.2M | ||
| Q1 24 | $325.9M | $410.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $647.8M | ||
| Q3 25 | $401.2M | $631.9M | ||
| Q2 25 | $156.3M | $635.8M | ||
| Q1 25 | $164.2M | $683.3M | ||
| Q4 24 | $228.5M | $679.6M | ||
| Q3 24 | $237.1M | $638.8M | ||
| Q2 24 | $264.3M | $596.2M | ||
| Q1 24 | $266.7M | $547.9M |
| Q4 25 | $1.1B | $836.7M | ||
| Q3 25 | $1.1B | $823.6M | ||
| Q2 25 | $821.4M | $801.7M | ||
| Q1 25 | $807.3M | $846.5M | ||
| Q4 24 | $885.1M | $840.6M | ||
| Q3 24 | $901.9M | $784.3M | ||
| Q2 24 | $904.5M | $714.6M | ||
| Q1 24 | $831.9M | $655.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $38.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $38.4M |
| 自由现金流率自由现金流/营收 | -7.1% | 19.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 1.58× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $38.4M | ||
| Q3 25 | $108.5M | $54.5M | ||
| Q2 25 | $4.4M | $43.9M | ||
| Q1 25 | $-53.4M | $5.1M | ||
| Q4 24 | $19.4M | $59.3M | ||
| Q3 24 | $34.1M | $73.8M | ||
| Q2 24 | $-8.3M | $41.2M | ||
| Q1 24 | $-133.0M | $23.8M |
| Q4 25 | $-14.3M | $38.4M | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | $43.9M | ||
| Q1 25 | $-53.4M | $5.0M | ||
| Q4 24 | $19.3M | $59.2M | ||
| Q3 24 | — | $72.2M | ||
| Q2 24 | $-8.4M | $40.8M | ||
| Q1 24 | $-133.3M | — |
| Q4 25 | -7.1% | 19.0% | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | 22.6% | ||
| Q1 25 | -32.0% | 3.2% | ||
| Q4 24 | 9.1% | 32.5% | ||
| Q3 24 | — | 39.5% | ||
| Q2 24 | -4.2% | 24.9% | ||
| Q1 24 | -77.3% | — |
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.2% | 0.0% |
| Q4 25 | — | 1.58× | ||
| Q3 25 | 0.50× | 2.77× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 1.93× | ||
| Q3 24 | — | 1.56× | ||
| Q2 24 | — | 1.16× | ||
| Q1 24 | — | 0.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CORT
暂无分部数据
